$35 Mil. Timm Medical Acquisition Broadens Endocare Urology Market
This article was originally published in The Gray Sheet
Executive Summary
Endocare's Feb. 21 acquisition of Timm Medical Technolgies provides a much-enlarged customer base for its urology product offering
You may also be interested in...
Cryoablation Or Brachytherapy? Endocare Promotes Prostate First-Line Option
Endocare is hoping that the results of an eight-year 590-patient registry study will convince more urologists to use cryoablation as an alternative to brachytherapy for first-line treatment of prostate cancer
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”